| Symbol
| MYCN
| contributors: mct/pgu - updated : 08-04-2017
|
| HGNC name
| v-myc myelocytomatosis viral related oncogene, neuroblastoma derived (avian)
|
| HGNC id
| 7559
|
| Other morbid association(s)
|
| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| tumoral
|
| amplification
|
|
|
in neuroblastoma, amplification is associated with rapid tumor progression and poor prognosis  | | tumoral
|
| amplification
|
|
| |
in tumors with MYCN amplification and low TPX2 index, a favorable outcome whereas in tumors with normal MYCN copy number and high TPX2 index, the prognosis is extremely poor | | tumoral
|
|
|
|
| |
copy number gain is relatively common in Wilms' tumor | | tumoral
|
| amplification
|
|
| |
in neuroblastoma | | tumoral
| germinal mutation
|
|
| gain of function
| |
MYCN gain is a germline aberration, with a significant role for MYCN dysregulation in the molecular biology of Wilms tumour | | tumoral
|
|
| --over
|
| |
frequently overexpressed in pediatric T-ALL | |
Variant & Polymorphism
| 
| |
| Candidate gene
| can drive medulloblastoma (initiation, progression and maintenance) independently of SHH |
Marker
Therapy target
|
|
| System | Type | Disorder | Pubmed |
|---|
| cancer | brain | glioma/neuroblstoma | |
| MYCN expression can be reduced by inhibiting the activity of ALK, suggesting a promising therapeutic approach for the treatment of neuroblastoma patients harbouring MYCN and ALK genes amplification or ALK mutations |
| | |
|
| in N-myc mouse mutants, loss of the lateral canal, fusion of the cochlea with the sacculus and utriculus, and stunted outgrowth of the cochlea |